VolitionRx Limited (NYSE MKT:VNRX) is to team up again with Hvidovre Hospital in Copenhagen in one of the largest medical studies ever undertaken in Europe.
Up to 90,000 samples will be taken from 30,000 patients to assess the ability of the NuQ blood test to detect colorectal and other cancers.
VolitionRx will assess whether, and how early, its NuQ assays detect cancer in samples taken before the definitive diagnosis of colorectal cancer.
All blood samples will be accompanied by up to 120 clinical information data points with first results expected by end 2018.
“Each sample collected will be sufficient for multiple NuQ tests and the study will form the basis for our product pipeline in multiple cancers for many years to come,” said Jake Micallef, chief scientific officer at the US–listed company.
VolitionRx currently has a number of other studies underway with its first commercial product, the NuQ colorectal cancer triage test, scheduled for release early next year.
To fund the new study, VolitionRx will make payments of US$1.1mln in each of the first two years of the study (Phase I) with an option to continue at a similar funding level for a further four years.
Story by ProactiveInvestors